Androgen Receptor Expression In Benign Prostatic Hyperplasia And Prostate Cancer

Main Article Content

Anandia Putriyuni
Nana Liana


AR expression, benign prostatic hyperplasia, prostate cancer


Background: Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) require androgen/androgen receptor (AR) signals. It plays an important role in the development of BPH; the initiation, growth, and progressivity of PCa, but the mechanism of AR in both of them remains unclear.
Objective: This study aims to evaluate the expression of AR in BPH and PCa.
Methods: Analytical study with cross-sectional design on a sample of 56 cases of BPH and PCa, respectively. The sampling was from the Anatomic Pathology laboratory in West Sumatera. Immunohistochemical (IHC) staining of AR to analyze protein expression semi-quantitatively. High expression of AR was set as strong interpretation.
Results: Mostly AR expression was high in BPH at 98.21% (55 cases) whereas high AR expression of PCa in tumor cells was slightly more in 51.79% (29 cases) than low AR expression. Most cases of PCa were Gleason score 9, namely 25 (44.64%) cases, and high AR expression in 29 (51.79%) cases. High-grade Gleason score (Gleason score 8-10) with high AR expression was more than low-grade
Gleason score (Gleason score ≤ 7). There was a statistically significant association between AR expression and Gleason score (p=0.018).
Conclusion: Activation of AR pathway is crucial for the development and progression of BPH and PCa. High AR expression was revealed most in epithelial and stromal cells of BPH, but it showed half of the tumor cells in PCa. The AR expression in tumor cells of PCa should be examined in cases to determine patient prognosis.

Abstract 306 | pdf Downloads 137


1. Andry, J. F., Tannady, H., Rembulan, G. D., & Rianto, A. (2022). The importance of big data for healthcare and its usage in clinical statistics of cardiovascular disease. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 107–115.
2. Andry, J. F., Rembulan, G. D., Salim, E. L., Fatmawati, E., & Tannady, H. (2023). Big Data Analytics in Healthcare: COVID-19 Indonesia Clustering. Journal of Population Therapeutics and Clinical Pharmacology, 30(4), 290–300.
3. Bashir, M. N. (2015). Epidemiology of prostate cancer. Asian Pacific Journal of Cancer Prevention, 16(13), 5137–5141.
4. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424.
5. Chen, R., Ren, S., Yiu, M. K., Fai, N. C., Cheng, W. S., Ian, L. H., Naito, S., Matsuda, T., Kehinde, E., Kural, A., Chiu, J. Y., Umbas, R., Wei, Q., Shi, X., Zhou, L., Huang, J., Huang, Y., Xie, L., Ma, L., … Sun, Y. (2014). Prostate cancer in Asia: A collaborative report. Asian Journal of Urology, 1(1), 15–29.
6. Chen, Y., Lin, Y., Nie, P., Jiang, W., Liu, Y., Yuan, R., Li, M., Zhao, S., Lin, H., Li, P., Zhang, J., Hu, Z., Xu, J., & Zhu, X. (2017). Associations of prostate-specific antigen, prostate carcinoma tissue gleason score, and androgen receptor expression with bone metastasis in patients with prostate carcinoma. Medical Science Monitor, 23, 1768–1774.
7. Crumbaker, M., Khoja, L., & Joshua, A. M. (2017). AR signaling and the PI3K pathway in prostate cancer. Cancers, 9(4), 1–15.
8. Dai, C., Heemers, H., & Sharifi, N. (2017). Androgen signaling in prostate cancer. Cold Spring Harbor Perspectives in Medicine, 7(9), 1–18.
9. Devlin, C. M., Simms, M. S., & Maitland, N. J. (2021). Benign prostatic hyperplasia – what do we know? BJU International, 127(4), 389–399.
10. Hashmi, A. A., Mudassir, G., Irfan, M., Hussain, Z. F., Hashmi, S. K., Asif, H., Nisar, L., Naeem, M., & Faridi, N. (2019). Prognostic significance of high androgen receptor expression in prostatic acinar adenocarcinoma. Asian Pacific Journal of Cancer Prevention, 20(3), 893–896.
11. Hetzl, A. C., Fávaro, W. J., Billis, A., Ferreira, U., & Cagnon, V. H. A. (2012). Steroid hormone receptors, matrix metalloproteinases, insulin-like growth factor, and dystroglycans interactions in prostatic diseases in the elderly men. Microscopy Research and Technique, 75(9), 1197–1205.
12. Husain, I., Shukla, S., Soni, P., & Husain, N. (2016). Role of androgen receptor in prostatic neoplasia versus hyperplasia. Journal of Cancer Research and Therapeutics, 12(1), 112–116.
13. Izumi, K., Mizokami, A., Lin, W. J., Lai, K. P., & Chang, C. (2013). Androgen receptor roles in the development of benign prostate hyperplasia. American Journal of Pathology, 182(6), 1942–1949.
14. Kishorebabu, A., Sree, N., & Chandralekha, P. (2019). A Review on Benign Prostatic Hyperplasia. World Journal of Current Medical and Pharmaceutical Research, 1, 192–197.
15. Lekshmy, K., & Prema, N. (2019). Study of Various Prognostic Factors in Prostate Cancer and its Correlation with Androgen Receptor Expression. Journal of Evolution of Medical and Dental Sciences, 8(34), 2687–2693.
16. Lim, K. Bin. (2017). Epidemiology of clinical benign prostatic hyperplasia. Asian Journal of Urology, 4(3), 148–151.
17. Madersbacher, S., Sampson, N., & Culig, Z. (2019). Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology, 65(5), 458–464.
18. Putriyuni, A., & Nurwiyeni, N. (2022). Ekspresi Tinggi Androgen Receptor Sebagai Penentu Prognosis Adenokarsinoma Prostat di Sumatera Barat. HEME: Health and Medical Journal, IV(1), 8–15.
19. Putriyuni, A., & Oktora, M. Z. (2020). Androgen Receptor Expression of Prostate Cancer Correlates with Gleason Score and Perineural Invasion in West Sumatera, Indonesia. International Journal of Medical Science and Clinical Invention, 7(11), 5125–5129.
20. Song, L., Shen, W., Zhang, H., Wang, Q., Wang, Y., & Zhou, Z. (2016). Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia. Bosnian Journal of Basic Medical Sciences, 16(3), 201–208.
21. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
22. The Global Cancer Observatory. (2020). Cancer Incident in Indonesia. International Agency for Research on Cancer, 858, 1–2.
23. Van Der Sluis, T. M., Meuleman, E. J. H., Van Moorselaar, R. J. A., Bui, H. N., Blankenstein, M. A., Heijboer, A. C., & Vis, A. N. (2012). Intraprostatic testosterone and dihydrotestosterone. Part II: Concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer. BJU International, 109(2), 183–188.
24. Vickman, R. E., Franco, O. E., Moline, D. C., Vander Griend, D. J., Thumbikat, P., & Hayward, S. W. (2020). The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian Journal of Urology, 7(3), 191–202.